JPH1025251A - 抗ｔｎｆ抗体による敗血症性シヨツクの治療 - Google Patents
抗ｔｎｆ抗体による敗血症性シヨツクの治療Info
- Publication number
- JPH1025251A JPH1025251A JP9054254A JP5425497A JPH1025251A JP H1025251 A JPH1025251 A JP H1025251A JP 9054254 A JP9054254 A JP 9054254A JP 5425497 A JP5425497 A JP 5425497A JP H1025251 A JPH1025251 A JP H1025251A
- Authority
- JP
- Japan
- Prior art keywords
- shock
- tnf
- septic shock
- treatment
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010040070 Septic Shock Diseases 0.000 title claims abstract description 42
- 230000036303 septic shock Effects 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title description 16
- 241000124008 Mammalia Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 206010040560 shock Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 5
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 42
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 42
- 230000035939 shock Effects 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 241000282887 Suidae Species 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 14
- 208000001953 Hypotension Diseases 0.000 description 8
- 230000036543 hypotension Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000002635 electroconvulsive therapy Methods 0.000 description 7
- 231100000284 endotoxic Toxicity 0.000 description 7
- 230000002346 endotoxic effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 230000002612 cardiopulmonary effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010053159 Organ failure Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 206010043089 tachypnoea Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 239000002396 thromboxane receptor blocking agent Substances 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HOLWINOWZVORSA-UHFFFAOYSA-N 3-(1,2,3,4-tetrahydrocarbazol-9-yl)propanoic acid Chemical compound C12=CC=CC=C2N(CCC(=O)O)C2=C1CCCC2 HOLWINOWZVORSA-UHFFFAOYSA-N 0.000 description 1
- -1 4- Fluorophenyl-sulfonamido Chemical group 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000035581 baroreflex Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002633 shock therapy Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60902296A | 1996-02-29 | 1996-02-29 | |
| US08/609022 | 1996-02-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH1025251A true JPH1025251A (ja) | 1998-01-27 |
| JPH1025251A5 JPH1025251A5 (enExample) | 2005-01-20 |
Family
ID=24439040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9054254A Pending JPH1025251A (ja) | 1996-02-29 | 1997-02-24 | 抗ｔｎｆ抗体による敗血症性シヨツクの治療 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0791360A3 (enExample) |
| JP (1) | JPH1025251A (enExample) |
| AU (1) | AU1487597A (enExample) |
| CA (1) | CA2198316A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6659212B2 (en) | 2000-05-06 | 2003-12-09 | Daimlerchrysler Ag | Hybrid drive for a motor vehicle with an exhaust gas turbocharger |
| WO2011158904A1 (ja) | 2010-06-18 | 2011-12-22 | 株式会社林原生物化学研究所 | アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161828A1 (en) * | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8806339D0 (en) * | 1988-03-17 | 1988-04-13 | Hoffmann La Roche | Monoclonal antibodies |
| GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
-
1997
- 1997-02-19 EP EP97102619A patent/EP0791360A3/en not_active Withdrawn
- 1997-02-24 AU AU14875/97A patent/AU1487597A/en not_active Abandoned
- 1997-02-24 CA CA002198316A patent/CA2198316A1/en not_active Abandoned
- 1997-02-24 JP JP9054254A patent/JPH1025251A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6659212B2 (en) | 2000-05-06 | 2003-12-09 | Daimlerchrysler Ag | Hybrid drive for a motor vehicle with an exhaust gas turbocharger |
| WO2011158904A1 (ja) | 2010-06-18 | 2011-12-22 | 株式会社林原生物化学研究所 | アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤 |
| US9301968B2 (en) | 2010-06-18 | 2016-04-05 | Hayashibara Co., Ltd. | Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient |
| US9757408B2 (en) | 2010-06-18 | 2017-09-12 | Hayashibara Co., Ltd. | Therapeutic agent for inflammatory diseases, containing adenosine N1-oxide as an effective ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1487597A (en) | 1997-09-04 |
| EP0791360A2 (en) | 1997-08-27 |
| EP0791360A3 (en) | 1997-09-24 |
| CA2198316A1 (en) | 1997-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sager et al. | Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction | |
| Holler et al. | Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F) | |
| Deitch | Multiple organ failure pathophysiology and potential future therapy | |
| EP0346078A2 (en) | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma | |
| O'Dea et al. | Lung-marginated monocytes modulate pulmonary microvascular injury during early endotoxemia | |
| EP0585705A1 (en) | Use of anti-TNF to treat bacterial meningitis | |
| CA2134966C (en) | Antibodies with specificity for multiple adhesion molecules | |
| WHERRY et al. | Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies | |
| Feng et al. | Bone marrow MyD88 signaling modulates neutrophil function and ischemic myocardial injury | |
| CN113660951A (zh) | 含有抗il-6受体抗体的抑制bbb功能低下的抑制剂 | |
| CN112969711A (zh) | 使用克拉扎珠单抗脱敏和改善hla致敏患者中的肾脏移植 | |
| US5607916A (en) | Method and composition for the treatment of septic shock | |
| JPH1025251A (ja) | 抗ｔｎｆ抗体による敗血症性シヨツクの治療 | |
| AU2005232653B2 (en) | Methods of treating autoimmune and inflammatory diseases | |
| JP5583575B2 (ja) | 感染症と関連炎症過程の治療のためのタンパク質生成物 | |
| US20110262456A1 (en) | Method of treating ischemia reperfusion injury | |
| JP2005516907A (ja) | 霊長類ｉｆｎ−ガンマ結合分子の使用 | |
| EP0565642A1 (en) | Method of preventing inflammatory damage | |
| US20210228695A1 (en) | Pic1 peptide compositions and methods of use thereof for treatment of drug-induced immune hemolytic anemia | |
| Furebring et al. | Differential expression of the C5a receptor and complement receptors 1 and 3 after LPS stimulation of neutrophils and monocytes | |
| Hocking et al. | Dextran sulfate inhibits PMN-dependent hydrostatic pulmonary edema induced by tumor necrosis factor | |
| US20200289612A1 (en) | Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes | |
| UA78516C2 (en) | Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity | |
| US20050042202A1 (en) | Compositions for and methods of treating and preventing sirs/sepsis | |
| Smith | Treatment of septic shock with immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070509 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070516 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071106 |